The most common side effect
Nausea is the side effect people on semaglutide ask about most, because it is the one the label reports most. This guide sets out what the FDA-approved prescribing information for Wegovy® says about it, how often, when and why, what the label allows a provider to do, the practical steps that published sources support, and the point at which nausea stops being a nuisance and becomes a reason to seek care.
This is general information and not medical advice. The figures describe Wegovy®, the branded product, in its trials. Personalized Compounded semaglutide, which Bodi Envi’s programs may include, is not FDA-approved, was not studied in those trials and is not equivalent to the approved product. Your licensed provider is the person to ask about your own symptoms, and the care team messaging in Bodi Envi’s programs exists for exactly this.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What the label reports for brand name versions
The Wegovy® label reports nausea in 44 percent of adults treated with 2.4 mg for weight reduction, against 16 percent on placebo, across three trials in which 2,116 adults took the medication for up to 68 weeks. That makes it the most common adverse reaction by a wide margin; the next, diarrhea, was 30 percent. Vomiting, which is related, was 24 percent against 6 percent. Nausea was also the most common reason for stopping treatment: 1.8 percent of treated patients discontinued because of it against 0.2 percent on placebo, with vomiting and diarrhea the next most common reasons. Severe gastrointestinal adverse reactions of any kind were reported in 4.1 percent of treated patients against 0.9 percent.
Two things the figures do not say are worth stating. Forty-four percent means that most treated participants did not report nausea at all. And the figure counts anyone who reported it at any point over 68 weeks, not people who had it continuously. This information is a study for the brand name product; personalized compounded versions are different products and cannot be compared to this brand study. This is for educational purposes only, and personalized compounded products cannot be expected to produce the results described above for the brand study.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
When it tends to occur
The label does not give a week by week timeline for nausea, but it says two things that place it. The escalation schedule, a starting dose of 0.25 mg rising in four week steps to a maintenance dose, exists to reduce the risk of gastrointestinal adverse reactions, and a provider may delay a step by four weeks if a dose is not tolerated. The label also says that if two or more consecutive doses are missed, escalation should restart at a lower dose for the same reason, which implies that tolerance is built by staying on the medication and lost when it is out of the system.
STEP 1, the reference trial published in the New England Journal of Medicine in 2021, adds the trajectory. Its abstract on PubMed describes the nausea and diarrhea seen as typically transient and mild to moderate in severity, subsiding with time. Read together, the label and the trial point to the escalation phase, and the weeks after each dose increase, as the period when nausea is most likely, with most cases easing as the body adjusts. The information above is strictly for the brand name version; personalized compounded versions are different products, and studies for the brand cannot be applied to the compounded versions.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
Why it happens
The label explains the mechanism in its section on oral medications: semaglutide causes a delay of gastric emptying. Food stays in the stomach longer. That is part of how the medication produces the feeling of fullness that reduces intake, and it is also what produces nausea, along with bloating, reflux and belching, all of which appear in the label’s table of common reactions. The same delay is why the label warns that the absorption of oral medications can be affected.
A 2026 narrative review of adverse events with incretin-based therapies, published in Drug Design, Development and Therapy and found through PubMed, synthesised sixty studies and safety reports and concluded that the common gastrointestinal adverse events predominantly reflect predictable pharmacological and physiological effects rather than off-target toxicity, that they are the principal cause of treatment discontinuation, and that aligning dose escalation and monitoring with the individual patient’s gastrointestinal tolerability is the sensible response. That is the same logic as the label’s escalation schedule, stated from the evidence side.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What the label says a provider may do
The label gives a provider explicit room. If a patient does not tolerate a dose during escalation, the provider may consider delaying the next increase by four weeks. In choosing between the maintenance doses, the provider is told to consider treatment response and tolerability. And the label’s pharmacokinetics, a half-life of about a week, explain why holding a dose for a few weeks is a meaningful adjustment: the level in the body takes several weeks to settle at each step.
With a compounded prescription, which is measured from a vial rather than delivered by a fixed dose pen, the provider can hold a dose, slow the escalation, or lower the dose, and those are the provider’s decisions to make. The FDA’s statement on unapproved GLP-1 drugs, dated September 1, 2026, reports adverse events including nausea and vomiting in patients given personalized compounded semaglutide in doses beyond what the approved label describes, and reports hospitalizations linked to measuring errors; the one thing not to do about nausea is to adjust your own dose in either direction.
Practical steps published sources support
This site reports only steps that a label or a cited paper supports, so the list is short and specific.
Drink fluids. The Wegovy® medication guide says that diarrhea, nausea and vomiting may cause dehydration, that dehydration may cause kidney problems, and that it is important to drink fluids to reduce that chance. The label’s warning on acute kidney injury ties most reported cases to dehydration from gastrointestinal reactions.
Eat smaller amounts. A 2026 narrative review in Nutrition in Clinical Practice, found through PubMed, reports that these medications significantly reduce meal size and may reduce overall water intake, that most patients will experience gastrointestinal side effects, and that those effects can often be managed with dietary adjustments. Smaller meals and steady fluids follow directly from that finding. What to eat beyond that is a question for your provider, and the guide on this site to eating well on treatment covers only what a cited source supports.
Keep the schedule. Because the label ties tolerance to steady exposure and says to restart escalation lower after missed doses, skipping doses to avoid nausea can make the next dose harder rather than easier. If you have missed doses, ask your care team how to proceed.
Report persistent symptoms. The label’s counselling section asks providers to tell patients to report persistent or extended nausea, vomiting or diarrhea promptly.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
When to contact your provider or seek care
The label draws the line at persistence and severity. Nausea, vomiting or diarrhea that does not go away should be reported to your provider because of the risk of dehydration and kidney injury. Severe abdominal pain that does not go away, sometimes radiating to the back, with or without nausea or vomiting, may signal pancreatitis; the label says to stop the medication promptly and contact your provider. Vomiting with the signs of dehydration, or an inability to keep fluids down, is a reason to seek care rather than wait. And nausea accompanied by symptoms the label lists under its other warnings, such as pain in the upper abdomen with fever or yellowing of the skin or eyes, which it names as signs of gallbladder problems, needs prompt attention.
For anything severe, seek emergency care first.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What the care team messaging is for
Bodi Envi’s programs include messaging with your care team through the patient portal, and nausea is the most common reason to use it. Message when a dose increase brings nausea that does not ease, when nausea is stopping you from eating or drinking normally, when you have missed doses because of it, or when you are unsure whether it is the medication at all. A licensed provider, through Wasef Health, PC for applicable programs, makes the clinical decisions, and the label’s own tools, slowing the escalation or choosing a lower dose, are available to them.
Bodi Envi is a telehealth platform and not a medical practice, pharmacy or medication manufacturer. Personalized Compounded semaglutide is not FDA-approved and is not equivalent to Wegovy®; the figures in this guide describe the branded product. This is general information and not medical advice, and your licensed provider is the person to ask.